AH
Therapeutic Areas
GRAIL Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Galleri® Test | Multi-Cancer Early Detection (MCED) | Approved/Commercial |
| REACH/Galleri-Medicare Study | Real-world clinical impact of Galleri | Observational Study |
| PATHFINDER 2 Study | Clinical implementation of Galleri | Interventional Study |
| NHS-Galleri Trial | Population screening utility of Galleri | Phase 3 |
| SUMMIT Study | MCED in lower-risk population | Observational Study |
| STRIVE Study | Refining Galleri prediction in women | Observational Study |
| CCGA Study | Foundational assay development for MCED | Observational Study |
| PATHFINDER Study | Early clinical implementation of MCED | Interventional Study |
Leadership Team at GRAIL
BR
Bob Ragusa
Chief Executive Officer and Board Member
JO
Joshua Ofman
President
AF
Aaron Freidin
Chief Financial Officer
AB
Abram Barth
Chief Legal Officer, Corporate Secretary
SH
Sir Harpal Kumar
Chief Scientific Officer & President International
AP
Andy Partridge
Chief Commercial Officer
SA
Satnam Alag
Senior Vice President, Software Engineering and Chief Security Officer
PC
Paul Ciccolella
Senior Vice President, Global Development & Operations
EF
Eric Fung
SVP, Clinical Development
LP
Linda Peters
SVP, Quality & Regulatory